— At Median Follow-Up of 24.2 Months, No Additional Risks of Adverse Events Related to Yescarta Were Observed —
— Findings Also Suggest Efficacy Trend with Median Progression-Free Survival and Durability of Response of More Than a Year —
— Data Presented Orally at the 2024 American Society of Clinical Oncology Annual Meeting —
Kite, a Gilead Company (NASDAQ:GILD), announced data from a pilot study in collaboration with Dana-Farber Cancer Institute that demonstrate Yescarta® (axicabtagene ciloleucel) is well-tolerated in patients living with relapsed or refractory (R/R) primary or secondary central nervous system lymphoma (PCNSL and SCNSL). The findings, which also suggest a trend in efficacy, were presented today in an oral session (Abstract #2006) at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
